Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium
Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the associati...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 语言: | English |
| 出版: |
BioMed Central
2016
|
| _version_ | 1826300063475826688 |
|---|---|
| author | Ordóñez-Mena, J Schöttker, B Mons, U Jenab, M Freisling, H Bueno-de-Mesquita, B O'Doherty, MG Scott, A Kee, F Stricker, B Hofman, A de Keyser, C Ruiter, R Söderberg, S Jousilahti, P Kuulasmaa, K Freedman, N Wilsgaard, T de Groot, L Kampman, E Håkansson, N Orsini, N Wolk, A Nilsson, L Tjønneland, A Pająk, A Malyutina, S Kubínová, R Tamosiunas, A Bobak, M Katsoulis, M Orfanos, P Boffetta, P Trichopoulou, A Brenner, H |
| author_facet | Ordóñez-Mena, J Schöttker, B Mons, U Jenab, M Freisling, H Bueno-de-Mesquita, B O'Doherty, MG Scott, A Kee, F Stricker, B Hofman, A de Keyser, C Ruiter, R Söderberg, S Jousilahti, P Kuulasmaa, K Freedman, N Wilsgaard, T de Groot, L Kampman, E Håkansson, N Orsini, N Wolk, A Nilsson, L Tjønneland, A Pająk, A Malyutina, S Kubínová, R Tamosiunas, A Bobak, M Katsoulis, M Orfanos, P Boffetta, P Trichopoulou, A Brenner, H |
| author_sort | Ordóñez-Mena, J |
| collection | OXFORD |
| description | Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. |
| first_indexed | 2024-03-07T05:11:27Z |
| format | Journal article |
| id | oxford-uuid:dbaef9d0-9ebc-4021-8e80-7c4b163c5eb1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:11:27Z |
| publishDate | 2016 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:dbaef9d0-9ebc-4021-8e80-7c4b163c5eb12022-03-27T09:12:29ZQuantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortiumJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:dbaef9d0-9ebc-4021-8e80-7c4b163c5eb1EnglishSymplectic Elements at OxfordBioMed Central2016Ordóñez-Mena, JSchöttker, BMons, UJenab, MFreisling, HBueno-de-Mesquita, BO'Doherty, MGScott, AKee, FStricker, BHofman, Ade Keyser, CRuiter, RSöderberg, SJousilahti, PKuulasmaa, KFreedman, NWilsgaard, Tde Groot, LKampman, EHåkansson, NOrsini, NWolk, ANilsson, LTjønneland, APająk, AMalyutina, SKubínová, RTamosiunas, ABobak, MKatsoulis, MOrfanos, PBoffetta, PTrichopoulou, ABrenner, HSmoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. |
| spellingShingle | Ordóñez-Mena, J Schöttker, B Mons, U Jenab, M Freisling, H Bueno-de-Mesquita, B O'Doherty, MG Scott, A Kee, F Stricker, B Hofman, A de Keyser, C Ruiter, R Söderberg, S Jousilahti, P Kuulasmaa, K Freedman, N Wilsgaard, T de Groot, L Kampman, E Håkansson, N Orsini, N Wolk, A Nilsson, L Tjønneland, A Pająk, A Malyutina, S Kubínová, R Tamosiunas, A Bobak, M Katsoulis, M Orfanos, P Boffetta, P Trichopoulou, A Brenner, H Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
| title | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
| title_full | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
| title_fullStr | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
| title_full_unstemmed | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
| title_short | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
| title_sort | quantification of the smoking associated cancer risk with rate advancement periods meta analysis of individual participant data from cohorts of the chances consortium |
| work_keys_str_mv | AT ordonezmenaj quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT schottkerb quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT monsu quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT jenabm quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT freislingh quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT buenodemesquitab quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT odohertymg quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT scotta quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT keef quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT strickerb quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT hofmana quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT dekeyserc quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT ruiterr quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT soderbergs quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT jousilahtip quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT kuulasmaak quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT freedmann quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT wilsgaardt quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT degrootl quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT kampmane quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT hakanssonn quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT orsinin quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT wolka quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT nilssonl quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT tjønnelanda quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT pajaka quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT malyutinas quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT kubinovar quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT tamosiunasa quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT bobakm quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT katsoulism quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT orfanosp quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT boffettap quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT trichopouloua quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT brennerh quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium |